Chengdu Yuman Biotechnology

Chengdu Yuman Biotechnology is a clinical-stage biopharmaceutical company based in Chengdu, China, dedicated to the development of innovative antibody-based therapies for cancer. The company focuses on engineering multi-functional biologics, including bispecific antibodies and fusion proteins, that target the complex signaling pathways within the tumor microenvironment. Its lead candidate, YM001, is a bifunctional fusion protein designed to simultaneously block the PD-L1 and TGF-β pathways, aiming to overcome immune evasion in advanced solid tumors. By integrating advanced protein design with deep biological insights, Yuman Biotech strives to provide more effective treatment options for patients with refractory malignancies. The company's pipeline includes several other early-stage programs targeting diverse oncogenic pathways and immune checkpoints.